Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics that selectively deplete pathogenic cells and disease-causing agents. Their proprietary Targeted Myeloid Engager and Phagocytosis Platform underpins their pipeline of first-in-class clinical and preclinical programs targeting oncology, autoimmune diseases, immunology, and neurology. Dren Bio aims to redefine treatment possibilities for patients with cancer and other serious diseases.